Mounjaro vs Zepbound: Dosing Differences Between Two Tirzepatide Brands

Mounjaro and Zepbound are both manufactured by Eli Lilly and both contain tirzepatide as their active ingredient. The key difference is regulatory: Mounjaro was FDA-approved in May 2022 for the treatment of type 2 diabetes, while Zepbound received approval in November 2023 specifically for chronic weight management in adults with obesity (BMI 30 or above) or overweight (BMI 27 or above) with at least one weight-related comorbidity.

This distinction matters primarily for insurance coverage and prescribing. The medication itself, its mechanism of action, and its administration are identical. Both are once-weekly subcutaneous injections delivered via single-dose prefilled pens.

Both Mounjaro and Zepbound are available in the same six dose strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg. The escalation schedule is also identical. Treatment starts at 2.5 mg weekly for four weeks, then increases to 5 mg. From 5 mg onward, the dose may be increased by 2.5 mg increments every four weeks based on tolerability and clinical response.

The minimum maintenance dose for both brands is 5 mg weekly, and the maximum is 15 mg weekly. There is no difference in the titration protocol between the diabetes indication (Mounjaro) and the weight management indication (Zepbound). Providers follow the same gradual escalation to minimize gastrointestinal side effects like nausea and diarrhea.

Both brand-name products come as prefilled single-dose pens. Each pen contains one dose at a specific strength, and you select the pen that matches your current prescribed dose. There is no need to measure or calculate units -- you simply inject the entire contents of the pen.

Compounded tirzepatide, by contrast, is dispensed in multi-dose vials at concentrations like 5 mg/mL, 10 mg/mL, or 20 mg/mL. Patients draw their dose using a U-100 insulin syringe and must convert milligrams to syringe units using the formula: units = (dose in mg / concentration in mg/mL) x 100. Compounded tirzepatide is not FDA-approved.

The biggest practical difference between Mounjaro and Zepbound is insurance coverage. Most commercial insurance plans cover Mounjaro for type 2 diabetes, often with prior authorization. Coverage for Zepbound for weight management is less common, as many insurers still classify anti-obesity medications as elective or non-essential.

Eli Lilly offers manufacturer savings programs for both branded products, which can reduce out-of-pocket costs for some commercially insured patients. Coverage and copays vary widely by plan and formulary tier, so patients should confirm their specific benefits before starting. Patients who pursue compounded tirzepatide instead should ask the licensed provider for the all-inclusive monthly cost of that program.

Some patients receive a Mounjaro prescription even when their primary goal is weight loss, if they also have type 2 diabetes or prediabetes. This is a legitimate clinical decision, not off-label use, since Mounjaro is approved for glycemic control in patients who may also benefit from weight reduction.

If you have type 2 diabetes, Mounjaro is the FDA-approved option and more likely to be covered by your insurance. If your primary goal is weight management and you do not have diabetes, Zepbound is the indicated brand, though coverage may be limited.

In practice, some patients access tirzepatide through compounded preparations from licensed compounding pharmacies rather than either brand-name pen. Compounded tirzepatide is not FDA-approved and is not reviewed by the FDA for safety, effectiveness, or quality. The dosing math is slightly more involved since you measure from a vial, but a dosage calculator makes the conversion straightforward. Patients considering compounded options should discuss the differences from FDA-approved branded products with a licensed provider.